AI & DIGITAL ONCOLOGY
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Can AI help deliver better medicines to patients?
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain
Embracing interdisciplinary collaboration for an AI-driven oncology
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
TARGETED THERAPIES
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Prolonged intertreatment interval improves outcomes to EGFR rechallenge in metastatic colorectal cancer
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
OPINIONS
Next-generation CAR-T cells are in the pipeline
Philippe Cassier
Target-led treatments for lung cancer – are they moving to the next level?
Tony SK Mok
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Lilian L. Siu
ctDNA and RNA-based tests are expanding colorectal cancer screening options
Frank A. Sinicrope
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Federica Di Nicolantonio
OPINIONS
Next-generation CAR-T cells are in the pipeline
Philippe Cassier
Target-led treatments for lung cancer – are they moving to the next level?
Tony SK Mok
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Lilian L. Siu
ctDNA and RNA-based tests are expanding colorectal cancer screening options
Frank A. Sinicrope
Decoding genomic and transcriptomic signatures in colorectal cancer – next steps?
Federica Di Nicolantonio